With Puma Biotechnology's U.S. Nerlynx sales shaping up at $300M in 2019, U.S. metastatic revenue coming in 2020, Europe launching in the first half of 2019 and rest-of-world territories with high royalties coming online in next 12-24 months, the Nerlynx brand is closing in on the $500M mark "faster than many investors may appreciate," Citi analyst Yigal Nochomovitz tells investors in a research note. The "list of excuses for not owning the launch now seems to be rapidly shrinking," adds the analyst after Puma reported Q4 results. He raised his price target for the shares to $70 from $67 and keeps a Buy rating on the shares.